Ortho-McNeil Topamax marketing documents subpoenaed
Executive Summary
Ortho-McNeil receives subpoena from Boston U.S. Attorney's Office requesting documents related to the company's sales and marketing of its anti-epileptic Topamax (topiramate). The Boston U.S. Attorney's Office is also conducting an investigation of Parke-Davis' (now Pfizer) promotions of its anti-epileptic Neurontin (gabapentin); the whistleblower case, alleging that the company violated the False Claims Act by promoting Neurontin for off-label uses, is pending in Massachusetts federal court (1"The Pink Sheet" Oct. 13, 2003, p. 15)...
You may also be interested in...
J&J Risperdal subpoena
Johnson & Johnson receives subpoena from HHS Office of the Inspector General for documents relating to the atypical antipsychotic Risperdal (risperidone). Boston U.S. Attorney's Office is investigating J&J's sales and marketing practices for the anti-epileptic Topamax (topiramate) (1"The Pink Sheet" Dec. 15, 2003, In Brief). Both products are widely used off-label...
Neurontin Ruling Is Guide For DoJ Off-Label Promotion Cases – Prosecutor
A recent ruling in the Neurontin "whistleblower" case lays the groundwork for future prosecutions involving off-label promotions under the False Claims Act, Philadelphia Assistant U.S. Attorney Virginia Gibson said Oct. 2 during an audioconference sponsored by the Pharmaceutical Compliance Forum
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.